This supports a model in which promoter hypermethylation of Kelch-like ECH-associated protein 1 (KEAP1) and consequent NRF2 activation may establish a survival-oriented, quiescent state through epigenetic reprogramming of NOTCH1, thereby facilitating long-term dormancy and resistance to therapy in lung cancer [49,50]. The gene discussed is KEAP1; the disease is lung cancer.